Expand all sections

Durvalumab

Imfinzi

Extended indication Non-small cell lung cancer (NSCLC) stage IIIB, unresectable.
Therapeutic value No judgement
Total cost 61,850,000.00

Product

Active substance Durvalumab
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Non-small cell lung cancer (NSCLC) stage IIIB, unresectable.
Proprietary name Imfinzi
Manufacturer AstraZeneca
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date October 2017
Expected Registration August 2018
Orphan drug No

Therapeutic value

Current treatment options Nivolumab, Pembrolizumab
Therapeutic value No judgement

Expected patient volume per year

Patient volume

50 - 2,424

Market share is generally not included unless otherwise stated.
References NKR; Fabrikant
Additional remarks NKR 2015: NSCLC stadium 3: 2424 diagnoses. Fabrikant: 50 patienten in 2019

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks Verwacht in lijn met andere immunotherapieën. €1098,16 voor nivolumab 10mg per ml fl 10 ml; €3355,96 voor pembrolizumab 25 mg per ml fl 4ml.

Potential total cost per year

Total cost

61,850,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No

Indication extension

Indication extension Yes
Indication extensions Nog voor veel indicaties in ontwikkeling, monotherapie en in combinatie met tremelimumab.

Other information

There is currently no futher information available.